Anzeige
Mehr »
Dienstag, 26.08.2025 - Börsentäglich über 12.000 News
Mega-Deal in Kanada: Katapultiert sich diese Aktie jetzt in die Top-Liga der Explorer?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QJRU | ISIN: US30233G2093 | Ticker-Symbol: PV3B
Tradegate
25.08.25 | 19:45
10,025 Euro
+0,37 % +0,037
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
EYEPOINT PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
EYEPOINT PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
9,86010,10025.08.
9,88410,09025.08.

Aktuelle News zur EYEPOINT PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
EYEPOINT PHARMACEUTICALS Aktie jetzt für 0€ handeln
18.08.EyePoint Pharmaceuticals, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)81WATERTOWN, Mass., Aug. 18, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients...
► Artikel lesen
14.08.Mizuho hebt Kursziel für EyePoint Pharmaceuticals auf 28 US-Dollar an14
14.08.EyePoint Pharmaceuticals stock price target raised to $28 at Mizuho1
13.08.EyePoint gibt Ausblick auf entscheidende Phase-3-Studien für Duravu9
07.08.EyePoint Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
07.08.EyePoint Pharmaceuticals, Inc. - 10-Q, Quarterly Report3
06.08.EyePoint signals 2026 LUGANO Phase III data and NDA filing for DURAVYU amid accelerated trial enrollment4
06.08.EyePoint Pharmaceuticals, Inc.: EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments200- Completed Phase 3 enrollment for DURAVYU in wet AMD with over 800 patients enrolled and randomized - - LUGANO and LUCIA trials each rapidly enrolled in seven months underscoring strong physician...
► Artikel lesen
06.08.EyePoint Pharmaceuticals, Inc. - 8-K, Current Report-
05.08.EyePoint Pharmaceuticals Q2 2025 Earnings Preview22
30.07.EyePoint Pharmaceuticals, Inc.: EyePoint to Report Second Quarter 2025 Financial Results on August 6, 20256
29.07.EyePoint Pharmaceuticals, Inc. - 8-K, Current Report1
29.07.EyePoint Pharmaceuticals, Inc.: EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU in Wet Age-Related Macular Degeneration 1.507- LUCIA pivotal Phase 3 trial enrolled and randomized over 400 patients in seven months, demonstrating continued strong enthusiasm for the DURAVYU pivotal program across the global retinal community...
► Artikel lesen
16.07.EyePoint Pharmaceuticals, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)147WATERTOWN, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients...
► Artikel lesen
20.06.EyePoint Pharmaceuticals, Inc. - 8-K, Current Report9
17.06.Forecasting The Future: 4 Analyst Projections For EyePoint Pharmaceuticals10
16.06.EyePoint Pharmaceuticals, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)277WATERTOWN, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients...
► Artikel lesen
30.05.EyePoint advances with Duravyu Phase III trial8
30.05.H.C. Wainwright maintains Buy on EyePoint with $22 target4
29.05.Analyst Expectations For EyePoint Pharmaceuticals' Future1
Weiter >>
51 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1